The one-year inhibition of IL-6 by tocilizumab increased lean mass in RA patients [108] and the use of bDMARDs seems to divide the risk of sarcopenia by half (OR 0.51) [109]. This evidence concerns the gene IL6 and rheumatoid arthritis.